ArticleKidney international reports2026
Markers of Mineral Metabolism in Children With CKD Stages 2 to 5D.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cystinosis-associated metabolic bone disease: pathogenesis and outcome.Pediatric nephrology (Berlin, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Changes in age- and sex-related markers for chronic kidney disease (CKD)-mineral and bone disorder (MBD) (CKD-MBD) across CKD stages 2 to 5D have not yet been studied in children. Methods: In this cross-sectional study, we investigated age, and where applicable, sex-related z-scores of 10 key markers for CKD-MBD in 170 children with stages 2-5D. Results: We identified distinct CKD stage-dependent changes in CKD-MBD markers. In CKD stage 2, elevated serum sclerostin (z-score: 0.97), total fibroblast growth factor 23 (FGF23) (z-score: 0.72) and alkaline phosphatase (AP) (z-score: 0.61) concentrations were observed in association with reduced serum phosphate (z-score: -0.62) and 1,25-dihydroxy vitamin D Conclusion: Elevated sclerostin, total FGF23, and AP concentrations in combination with reduced serum phosphate and (1,25(OH)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.